HRP20230864T1 - Pd-1 blokada nivolumabom kod refraktornog hodgkinovog limfoma - Google Patents
Pd-1 blokada nivolumabom kod refraktornog hodgkinovog limfoma Download PDFInfo
- Publication number
- HRP20230864T1 HRP20230864T1 HRP20230864TT HRP20230864T HRP20230864T1 HR P20230864 T1 HRP20230864 T1 HR P20230864T1 HR P20230864T T HRP20230864T T HR P20230864TT HR P20230864 T HRP20230864 T HR P20230864T HR P20230864 T1 HRP20230864 T1 HR P20230864T1
- Authority
- HR
- Croatia
- Prior art keywords
- nivolumab
- dose
- subject
- lymphoma
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344880P | 2016-06-02 | 2016-06-02 | |
| PCT/US2017/035492 WO2017210453A1 (en) | 2016-06-02 | 2017-06-01 | Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma |
| EP17730627.1A EP3463457B1 (en) | 2016-06-02 | 2017-06-01 | Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230864T1 true HRP20230864T1 (hr) | 2023-11-10 |
Family
ID=59067911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230864TT HRP20230864T1 (hr) | 2016-06-02 | 2017-06-01 | Pd-1 blokada nivolumabom kod refraktornog hodgkinovog limfoma |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11083790B2 (enExample) |
| EP (2) | EP3463457B1 (enExample) |
| JP (3) | JP7175198B2 (enExample) |
| KR (2) | KR20230038318A (enExample) |
| CN (1) | CN109475633A (enExample) |
| DK (1) | DK3463457T3 (enExample) |
| ES (1) | ES2954139T3 (enExample) |
| FI (1) | FI3463457T3 (enExample) |
| HR (1) | HRP20230864T1 (enExample) |
| HU (1) | HUE062398T2 (enExample) |
| LT (1) | LT3463457T (enExample) |
| PL (1) | PL3463457T3 (enExample) |
| PT (1) | PT3463457T (enExample) |
| RS (1) | RS64388B1 (enExample) |
| SI (1) | SI3463457T1 (enExample) |
| SM (1) | SMT202300290T1 (enExample) |
| WO (1) | WO2017210453A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| MX392711B (es) | 2015-08-11 | 2025-03-24 | Wuxi Biologics Ireland Ltd | Anticuerpos anti-pd-1 novedosos. |
| HUE062398T2 (hu) | 2016-06-02 | 2023-10-28 | Bristol Myers Squibb Co | PD-1 blokád nivolumabbal refrakter Hodgkin limfómában |
| MX390955B (es) | 2016-06-02 | 2025-03-19 | Seagen Inc | Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-cd30 para el tratamiento de linfoma. |
| US12668635B1 (en) | 2017-11-21 | 2026-06-30 | Arcus Biosciences, Inc. | Methods of treating solid tumors using an anti-PD-1 antibody or a fragment thereof |
| WO2019140150A1 (en) * | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
| CN119792515A (zh) * | 2018-02-13 | 2025-04-11 | 默沙东有限责任公司 | 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法 |
| CN113164599B (zh) * | 2018-12-24 | 2023-08-01 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
| KR20210146348A (ko) * | 2019-03-28 | 2021-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| WO2025136845A1 (en) * | 2023-12-19 | 2025-06-26 | Merck Sharp & Dohme Llc | Methods of treating a patient with a pd-1 antagonist |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| AU2001233027A1 (en) | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US20060032289A1 (en) | 2004-08-11 | 2006-02-16 | Pinnaduwage Lal A | Non-optical explosive sensor based on two-track piezoresistive microcantilever |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| ES2699965T3 (es) | 2011-03-10 | 2019-02-13 | Provectus Pharmatech Inc | Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| AU2013302696B9 (en) * | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| HUE062398T2 (hu) | 2016-06-02 | 2023-10-28 | Bristol Myers Squibb Co | PD-1 blokád nivolumabbal refrakter Hodgkin limfómában |
-
2017
- 2017-06-01 HU HUE17730627A patent/HUE062398T2/hu unknown
- 2017-06-01 PL PL17730627.1T patent/PL3463457T3/pl unknown
- 2017-06-01 HR HRP20230864TT patent/HRP20230864T1/hr unknown
- 2017-06-01 WO PCT/US2017/035492 patent/WO2017210453A1/en not_active Ceased
- 2017-06-01 PT PT177306271T patent/PT3463457T/pt unknown
- 2017-06-01 EP EP17730627.1A patent/EP3463457B1/en active Active
- 2017-06-01 KR KR1020237008131A patent/KR20230038318A/ko not_active Ceased
- 2017-06-01 SM SM20230290T patent/SMT202300290T1/it unknown
- 2017-06-01 SI SI201731382T patent/SI3463457T1/sl unknown
- 2017-06-01 DK DK17730627.1T patent/DK3463457T3/da active
- 2017-06-01 FI FIEP17730627.1T patent/FI3463457T3/fi active
- 2017-06-01 LT LTEPPCT/US2017/035492T patent/LT3463457T/lt unknown
- 2017-06-01 ES ES17730627T patent/ES2954139T3/es active Active
- 2017-06-01 CN CN201780047962.4A patent/CN109475633A/zh active Pending
- 2017-06-01 KR KR1020187037835A patent/KR20190015377A/ko not_active Ceased
- 2017-06-01 US US16/306,285 patent/US11083790B2/en active Active
- 2017-06-01 RS RS20230598A patent/RS64388B1/sr unknown
- 2017-06-01 JP JP2018563008A patent/JP7175198B2/ja active Active
- 2017-06-01 EP EP23174335.2A patent/EP4248990A3/en active Pending
-
2021
- 2021-08-09 US US17/397,221 patent/US20220025049A1/en not_active Abandoned
-
2022
- 2022-11-08 JP JP2022178836A patent/JP7568698B2/ja active Active
-
2024
- 2024-10-02 US US18/905,043 patent/US20250134996A1/en active Pending
- 2024-10-03 JP JP2024174007A patent/JP2025020119A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025020119A (ja) | 2025-02-12 |
| US20250134996A1 (en) | 2025-05-01 |
| EP3463457A1 (en) | 2019-04-10 |
| LT3463457T (lt) | 2023-09-11 |
| KR20190015377A (ko) | 2019-02-13 |
| PT3463457T (pt) | 2023-09-07 |
| US20190290757A1 (en) | 2019-09-26 |
| JP2023025012A (ja) | 2023-02-21 |
| JP7568698B2 (ja) | 2024-10-16 |
| RS64388B1 (sr) | 2023-08-31 |
| JP2019517504A (ja) | 2019-06-24 |
| PL3463457T3 (pl) | 2023-08-21 |
| FI3463457T3 (fi) | 2023-09-12 |
| US20220025049A1 (en) | 2022-01-27 |
| EP4248990A2 (en) | 2023-09-27 |
| HUE062398T2 (hu) | 2023-10-28 |
| KR20230038318A (ko) | 2023-03-17 |
| JP7175198B2 (ja) | 2022-11-18 |
| WO2017210453A1 (en) | 2017-12-07 |
| ES2954139T3 (es) | 2023-11-20 |
| SI3463457T1 (sl) | 2023-09-29 |
| EP3463457B1 (en) | 2023-06-28 |
| US11083790B2 (en) | 2021-08-10 |
| CN109475633A (zh) | 2019-03-15 |
| DK3463457T3 (da) | 2023-10-02 |
| EP4248990A3 (en) | 2024-01-03 |
| SMT202300290T1 (it) | 2023-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3463457T3 (fi) | Pd-1-esto nivolumabilla refraktaarinen hodgkinin lymfoomassa | |
| Van Beijnum et al. | The great escape; the hallmarks of resistance to antiangiogenic therapy | |
| WO2018191548A3 (en) | Complement factor d antagonist antibodies and conjugates thereof | |
| TN2016000094A1 (en) | Inhibitors of bruton's tyrosine kinase. | |
| MY209831A (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| JP2019526543A5 (enExample) | ||
| MX2018001263A (es) | Nueva combinacion para el uso en el tratamiento del cancer. | |
| NZ731735A (en) | Anti-pd-1 antibodies and methods of use thereof | |
| AR116121A1 (es) | Métodos de tratamiento del cáncer | |
| CL2018001548A1 (es) | Tratamiento de colestasis intrahepática y enfermedades del hígado relacionadas | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| MX2017005350A (es) | Terapia para la inhibicion de la replicacion del virus de arn monocatenario. | |
| MY204310A (en) | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | |
| EA201991650A1 (ru) | Способы лечения неврологических расстройств | |
| MX2021007899A (es) | Composiciones con inhibidor selectivo de la trans-se?alizacion de il-6. | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| WO2014167584A3 (en) | Herbal compositions for treating pain and skin disorders | |
| CN111465408A (zh) | 一种预防或治疗骨关节炎的方法和药物 | |
| EP3453391A4 (en) | STATINE-BASED NANOPARTICLE PREPARATION FOR IMPROVING THE FUNCTION OF STEM CELLS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND FUNCTIONALLY IMPROVED STEM CELLS THEREFORE FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
| MX2017013795A (es) | Combinaciones terapeuticas de tratamientos antivirales y antiinflamatorios. | |
| PE20160851A1 (es) | Formas de dosificacion farmaceuticas | |
| MA39912B1 (fr) | Dérivés de 2-aryl-4-hydroxy-1,3-thiazole comme antagonistes du trpm8, et leur utilisation dans le traitement de la neuralgie, de la douleur, de la bpco et de l'asthme. | |
| MY191923A (en) | Pyridone derivatives for the treatment of viral infections and further diseases | |
| WO2014153209A8 (en) | Antisense oligonucleotides for treatment of cancer stem cells | |
| MX364704B (es) | Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos. |